Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:29 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 196,718 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALL Clear all
Completed Phase 2 Interventional

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

NCT00048022
View directory record Official record
Conditions
Asthma
Interventions
Dual Integrin Antagonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
59
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Nov 3, 2026, 9:29 AM EST
Recruiting No phase listed Observational

Serum Inflammatory Protein Concentration During Dental Treatment

NCT07468929
View directory record Official record
Conditions
Periodontal Disease, Periodontal Surgery
Interventions
Blood samples for inflammatory markers, periodontal surgery, Periodontal maintenance, Non-surgical deep cleaning
Other · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 9:29 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia

NCT01098929
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 2 Interventional

Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

NCT00039429
View directory record Official record
Conditions
Kidney Cancer
Interventions
atrasentan hydrochloride
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
177
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 1 Interventional

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

NCT00489931
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions
VRC-AVIDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 9:29 AM EST
Recruiting Phase 1 Interventional

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

NCT07532902
View directory record Official record
Conditions
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
Interventions
BMS-986504, Ipilimumab, Nivolumab, 5-FU, Leucovorin, Oxaliplatin, Gemcitabine, Platinum
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 3, 2026, 9:29 AM EST
Completed Not applicable Interventional Results available

Strategies to Improve Pain and Enjoy Life

NCT03743402
View directory record Official record
Conditions
Chronic Pain
Interventions
Pain self-management training, video education, motivational interviewing, voluntary self-paced opioid taper, prescribing guidance for primary care provider, usual care
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

NCT06048302
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 9:29 AM EST
Terminated Phase 2 Interventional Accepts healthy volunteers

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953
View directory record Official record
Conditions
Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions
Erythropoietin, Saline placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
Up to 24 Hours
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Nov 3, 2026, 9:29 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients

NCT02463253
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 82 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 4 Interventional Results available

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Nov 3, 2026, 9:29 AM EST
Terminated Not applicable Interventional

Stress Index to Individualize Mechanical Ventilation in ARDS

NCT02871102
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Recruitment Maneuver with PEEP and Tidal Volume Optimization
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Nov 3, 2026, 9:29 AM EST
Not listed Phase 2 Interventional

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

NCT00449202
View directory record Official record
Conditions
Obesity
Interventions
oleoyl-estrone (MP 101)
Drug
Lead sponsor
Manhattan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2007 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 2 Interventional Results available

The Role of Contrast Enhanced Ultrasound in Appendicitis

NCT03687502
View directory record Official record
Conditions
Acute Appendicitis
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 3, 2026, 9:29 AM EST
Not listed No phase listed Observational

A Model to Identify Specific Predictors of Spatial Neglect Recovery

NCT00990353
View directory record Official record
Conditions
Spatial Neglect, Hemispatial Neglect, Hemineglect, Unilateral Neglect, Visual Spatial Neglect, Sensory Neglect
Interventions
Not listed
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
3
States / cities
Chester, New Jersey • Saddle Brook, New Jersey • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Nov 3, 2026, 9:29 AM EST
Completed No phase listed Observational

COVID-19 Endoscopy Survey

NCT04342637
View directory record Official record
Conditions
COVID-19
Interventions
Practice details
Other
Lead sponsor
Al-Azhar University
Other
Eligibility
30 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albertson, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 2 Interventional Results available

Study of SPG601 in Adult Men With Fragile X Syndrome

NCT06413537
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
SPG601, Placebo
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 3 Interventional Results available

EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries

NCT00896337
View directory record Official record
Conditions
Iliac Artery Stenosis
Interventions
Epic™ Nitinol Stent System, Anti-platelet therapy, Anti-coagulation therapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • Brandon, Florida • Fort Lauderdale, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 2 Interventional Results available

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

NCT01954745
View directory record Official record
Conditions
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Nov 3, 2026, 9:29 AM EST
Recruiting Phase 4 Interventional

Correction of Psoriatic T Cell Signatures by Deucravacitinib

NCT05858645
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
deucravacitinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 4 Interventional Results available

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

NCT01722045
View directory record Official record
Conditions
Age - Related Macular Degeneration (AMD)
Interventions
Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Nov 3, 2026, 9:29 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Nov 3, 2026, 9:29 AM EST